IPHA fundamentals
Innate Pharma S.A. financial statements, including revenue, expenses, and profit
The total revenue of IPHA for the last semiannual is 4.69 M USD, and it's 47.72% lower compared to the previous semiannual. The net income of H2 24 is -26.75 M USD.
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
TTM